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DEC1, also known as SHARP-2 or Stra13, plays important roles in embryonic development, proliferation, apoptosis and cell
differentiation in the mouse. DEC1 was recently identified as hypoxically induced in cDNA microarray studies of the human renal
carcinoma cell line RCC4, to be regulated through hypoxia-inducible factor (HIF)-1a and via HIF-1a, able to block adipocyte
differentiation. Nevertheless, its distribution and role in hypoxia and differentiation in human breast cancer are unknown. We
therefore examined the pattern and level of expression of DEC1 using immunohistochemistry in whole tissue sections in normal, in
situ and invasive breast carcinomas, and correlated the level of expression of DEC1 and clinicopathological factors and hypoxic
tumour markers in 253 invasive carcinomas on tissue microarrays. We observed an increase in DEC1 expression during progression
from normal to in situ and invasive carcinoma. Expression was not restricted to the tumour cell element but was also observed in
endothelial, fibroblasts and inflammatory cells. There was a significant positive correlation between DEC1 and tumour grade
(P¼0.01), HIF-1a (P¼0.04) and the hypoxically regulated gene angiogenin (Po0.0001), but no significant associations were
observed with patient age (P¼0.15), lymph node status (P¼0.8), tumour size (P¼0.3), oestrogen receptor (P¼0.45), epidermal
growth factor receptor (P¼0.27) or Chalkley vessel count (P¼0.45). There was no difference in relapse-free (P¼0.84) or overall
(P¼0.78) survival. These findings suggest that DEC1 plays an important role in the progression to invasive breast cancer and that it
may provide a mechanism by which hypoxia blocks tumour differentiation, and may contribute to a more aggressive phenotype.
Reversing this phenotype may alter the biological behaviour of individual tumours.
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Hypoxia is increasingly recognised to play a major role in
determining tumour behaviour being associated with an aggressive
phenotype and resistance to chemo- and radiotherapeutic inter-
ventions. The transcriptional complex hypoxia-inducible factor
(HIF) has emerged as a key regulator mediating many cellular
responses necessary to adapt to changes in oxygen tension
(reviewed in Maxwell et al, 2001; Goonewardene et al, 2002; Pugh
and Ratcliffe, 2003). The HIF complex is composed of a
heterodimer of HIF-1a or HIF-2a and HIF-b (also known as
aryl-hydrocarbon nuclear translocator). Hypoxia-inducible factor-
b is constitutively expressed and is involved in several transcrip-
tional systems, whereas the two HIF-a subunits are specific to the
hypoxic pathway. In normoxic conditions, the HIF-a units are
unstable since two prolyl residues within the oxygen-dependent
degradation domains of HIF-a subunits are hydroxylated by prolyl
hydroxylases and dioxygen as a co-substrate (reviewed in Pugh
and Ratcliffe, 2003). This results in one oxygen being incorporated
into the prolyl residue of HIF-a, allowing rapid targeting and
degradation by the proteasome pathway via the von Hippel–
Lindau (VHL) protein and the ubiquitin E3 ligase complex.
However, in hypoxia, as frequently occurs within tumours, there is
insufficient oxygen to allow this process resulting in HIF-a
stabilisation and translocation to the nucleus, where it is able to
bind HIF-b. The complex then recruits co-activators that bind
specific DNA hypoxia response elements (HREs), resulting in
increased mRNA transcription.
Many HIF target genes are beneficial to tumour, including those
involved in iron metabolism (e.g. transferrin), angiogenesis (e.g.
vascular endothelial growth factor), glucose metabolism (glucose
transporters), proliferation (insulin growth factor II), endothelial
adhesion and pH regulation (carbonic anhydrase IX) (Zund et al,
1996; Semenza, 2000; Wenger, 2000). Recently, using a cDNA
microarray in the renal carcinoma cell line RCC4, which was either
defective or competent for VHL, we identified DEC1 (differentially
expressed in chondrocytes) to be another such hypoxia-inducible
gene (Wykoff et al, 2000b).
DEC1 was originally identified independently by three groups
studying different mammalian systems of differentiation (Boudje-
lal et al, 1997; Rossner et al, 1997; Shen et al, 1997). DEC1 (also
known as split and hairy related protein (SHARP) 2 or stimulated
with retinoic acid (Stra) 13) is a 412 amino-acid transcription
factor whose RNA is expressed in most embryonic and adult Received 10 March 2004; revised 6 May 2004; accepted 19 July 2004
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ytissues. DEC1 shows high amino-acid sequence similarity to the
Drosophila hairy and enhancer of Split m7 and mammalian HES1
transcription factors across its basic helix–loop–helix (bHLH)
domain, but it lacks the C-terminal WRPW domain that accounts
for their transcriptional repressive functions, indicating that DEC1
is a member of a distinct bHLH subfamily. DEC1 binds to DNA,
demonstrates transcriptional repressive activity and interacts with
several subunits of RNA polymerase II, suggesting that DEC1
represses transcription through modulation of the basal transcrip-
tional machinery and histone deacetylase (Boudjelal et al, 1997;
Sun and Taneja, 2000).
DEC1 is reported to have roles in proliferation (Boudjelal et al,
1997), apoptosis (Li et al, 2002) and cell differentiation (Fisher et al,
1996). Indeed, it is possible that DEC1 functions as a HIF effector
to mediate the effect of hypoxia on differentiation, since oxygen
tension alters differentiation of cytotrophoblast, megakaryocytes,
osteochondrocytes, bone marrow cells, adipocytes and neurons
(Caniggia et al, 2000; Mostafa et al, 2000; Studer et al, 2000;
Lennon et al, 2001; Yun et al, 2002). Nevertheless, since little is
known about DEC1 function in human physiological and
pathological processes, we raised a polyclonal antibody to
investigate the expression profile of DEC1 in normal and
neoplastic tissues by immunohistochemistry to help determine
its role. This has shown DEC1 to be widely expressed in the nuclei
of cells in many tissues, but with a restricted pattern of expression.
Although others and we have also reported the expression of DEC1
in several tumour types (Ivanova et al, 2001; Li et al, 2002, 2003;
Giatromanolaki et al, 2003), the pattern and level of expression of
DEC1 in breast tissues and tumours have not been systematically
investigated and the potential role in this tumour type is unknown.
Thus, in order to characterise further the significance of DEC1 in
normal and neoplastic breast tissues, we have investigated the
distribution and level of expression of DEC1 and correlated this
with clinicopathological and hypoxic tumour markers in a large
series of breast carcinomas.
MATERIALS AND METHODS
Patients and tumours
Whole tissue sections from 15 pure in situ breast carcinomas (five
low, five intermediate and five high nuclear grade), 101 invasive
breast carcinomas and 14 histologically normal breast tissues
derived from reduction mammoplasties, together with micro-
arrayed tumour cores from 253 breast carcinomas, were collected
from patients undergoing surgery at the John Radcliffe Hospital,
Oxford, UK. Tumours were treated by mastectomy (n¼58) or
lumpectomy (n¼195), axillary node sampling with node status
confirmed histologically. Primary histological types where known
included 188 ductal carcinomas (not otherwise specified), 18
lobular and 15 others. Grading was performed according to the
modified Bloom and Richardson method. The clinicopathological
characteristics of the series are presented in Table 1. In patients
o50 years, adjuvant cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) was administered if tumours were node
positive, or oestrogen receptor (ER) negative and/or X3cm.
Patients X50 years with ER-negative, node-positive tumours also
received CMF. The median follow-up was 7.3 (range 0.4–11) years,
in which there were 89 relapses and 62 deaths.
DEC1 immunohistochemistry
Formalin-fixed paraffin-embedded sections (4mm) of normal and
primary breast tumours were immunostained with the rabbit
polyclonal antibody CW27 as described previously, using the
EnVision
TM Detection Kit, Peroxidase/DAB (DAKO, Denmark)
(Giatromanolaki et al, 2003). The pattern of DEC1 expression
was determined from whole tissue sections, whereas the
level of nuclear expression was derived using tissue microarrays.
One core from the tumour periphery, which is reported to
be most biologically relevant (Weidner et al, 1991), and the
following scoring system were used: negative¼0, weak nuclear
staining¼1, moderate nuclear staining¼2 or strong nuclear
staining¼3. Score 2 and 3 tumours were considered positive
for DEC1 in statistical analyses. Two observers assessed the
localisation and degree of cellular staining using a conference
microscope.
Assessment of HIF-1a, angiogenin and vascularity
The anti-HIF-1a protein monoclonal antibody ESEE 122 (Talks
et al, 2000) and rabbit polyclonal antibody against angiogenin
(ANG; Santa Cruz Biotechnology; catalogue number sc-
9044)(Hartmann et al, 1999; Hisai et al, 2003) were applied to
sections at dilutions of 1:40 and 1:100, respectively, followed by
the Envision-HRP kit (DAKO, Glostrup, Denmark). Evaluation of
HIF-1a was based on the intensity and extent of nuclear and
cytoplasmic reactivity as reported previously (Talks et al, 2000),
and angiogenin was scored with the same scoring system as for
Table 1 Correlation analyses between DEC1 and clinicopathological,
angiogenic and hypoxia markers for 253 invasive breast carcinomas studied
by tissue microarray
DEC1 negative DEC1 positive P-value
No. of patients 68 185
Age
o50 15 58 0.15
X50 53 127
Nodal status
Neg 37 104 0.80
Pos 31 81
Tumour size (cm)
p2cm 41 98 0.30
42cm 27 87
Grade
I 19 26 0.01*
II 16 56
III 12 56
ER
Neg 19 61 0.45
Pos 49 124
EGFR
Neg 30 67 0.27
Pos 37 114
Chalkley count
Low 3 29 0.45
High 5 23
Angiogenin
Neg 46 76 0.0001*
Pos 19 101
HIF-1a
Neg 54 124 0.04*
Pos 8 42
ER¼oestrogen receptor; EGFR¼epidermal growth factor receptor; HIF¼hypoxia-
inducible factor.
*Denotes significance, where no253 data are unavailable.
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yDEC1. Tumour vascularity was counted by scanning at low power
( 40–100) for the three areas of highest vascularity before using a
25-point Chalkley point eyepiece graticule at  250 (0.155mm
2)
over these hot spots. The graticule was orientated so that the
maximum number of points was on or within areas of highlighted
vessels. The mean of three graticule points for each tumour was
used in the statistical analysis, with the upper third used as a cut
point for categorical analysis as determined previously (Fox et al,
1995).
RESULTS
DEC1 expression in normal, in situ and invasive breast
carcinomas
Whole tissue sections DEC1 expression in normal human breast
tissues was weak and patchy, being mostly present in the nuclei
and occasionally in the cytoplasm of the epithelial elements.
Expression was present predominantly in the luminal epithelial
cells of the acini of terminal duct lobular units and in larger ducts
(Figure 1A and B), but myoepithelial cell staining was occasionally
present, which was enhanced in areas demonstrating myoid
metaplasia. The intensity of DEC1 expression was also increased
in areas of apocrine and columnar cell metaplasia. Weak
DEC1 expression was also observed in stromal cells of the
interlobular and intralobular stroma and in endothelial cells of
capillaries (Figure 1C). In in situ carcinomas, expression was
generally stronger both in the nucleus and the cytoplasm of the
neoplastic cells (Figure 1D). One of 15 cases was negative, four
cases showed weak staining, five cases moderate staining and five
showed strong staining. Expression of DEC1 was variable, both
within and between individually affected ducts (Figure 1D). No
enhancement was observed adjacent to areas of necrosis
and indeed an accentuated expression was observed at the
periphery of involved ducts, increasing in the cell layers away
from the edge of the necrosis and not immediately adjacent to it
(Figure 1E). In the 101 invasive carcinomas, expression of DEC1
was again nuclear but also cytoplasmic in 41 cases, and
immunopositivity was stronger and more homogenous throughout
the tumour than in normal or in situ carcinomas (Figure 1F). Two
tumours were negative, 40 showed weak staining, 24 moderate and
35 strong staining. Other tumour elements were also DEC1
positive, including fibroblasts, macrophages and endothelial cells
(Figure 1G and H) in 86 out of 101 (85%), 43 out of 101 (42%) and
79 out of 101 (78%) cases, respectively. Although not graded due to
the significant variability in the quantity of these elements,
expression was usually stronger than that observed in normal
tissues.
Tissue microarrays One (o1%) of 253 tumours was negative, 67
(26%) cases showed weak staining, 75 (30%) cases showed
moderate staining and 110 (44%) showed strong staining. In all,
68 were considered negative and 185 positive for the statistical
analysis. For cytoplasmic staining, 123 (49%) tumours were
positive and 130 (51%) were negative.
Relationship between DEC1 expression, clinicopathological
and hypoxic variables and survival
There was a significant positive correlation in 253 invasive
carcinomas from tissue microarrays between DEC1 and tumour
grade (P¼0.01), HIF-1a (P¼0.04) and the hypoxically regulated
gene (Hartmann et al, 1999) angiogenin (Po0.0001). No
significant associations were observed with patient age
(P¼0.15), lymph node status (P¼0.8), tumour size (P¼0.3), ER
(P¼0.45), epidermal growth factor receptor (P¼0.27) or Chalkley
vessel count (P¼0.45) (Table 1). There was no difference in
relapse-free (P¼0.84) or overall (P¼0.78) survival in a univariate
analysis of patients when tumours were stratified by DEC1
expression (Figure 2).
DISCUSSION
DEC1 is a new and structurally different class of bHLH protein.
Although little is known about its function in human physiological
and pathological processes, in the mouse DEC1 represses
adipocyte, mesodermal and endodermal differentiation but
promotes neuronal differentiation (Boudjelal et al, 1997; Yun
et al, 2002). It may also play a role in regulating peripheral T-cell
tolerance through elimination of activated lymphocytes (Sun
et al, 2001), affect cell proliferation (Sun and Taneja, 2000)
and apoptosis (Li et al, 2002). We and others have identified
DEC1 as a VHL target gene (Ivanov et al, 1998; Wykoff et al,
2000b). In view of the potential of DEC1 to regulate the
cellular responses to hypoxia in neoplasia through the
above processes, we have examined the pattern and level of
expression of DEC1 in normal and neoplastic human breast
tissues. In normal breast, we observed only a low level and
Figure 1 DEC1 expression in normal and neoplastic breast tissues.
Patchy and weak predominantly nuclear DEC1 expression in luminal
epithelial cells of normal acini (A). DEC1 in endothelial cells and fibroblasts
around vessels in normal breast (B). Myoepithelial and luminal DEC in a
normal large duct, together with stromal fibroblast positivity (C).
Intermediate nuclear grade ductal carcinoma in situ (DCIS) of predominant
solid pattern, showing moderate DEC1 expression that varies within and
between involved ducts (D). DEC1 in high nuclear-grade DCIS of comedo
type, showing gradual enhancement of expression towards the periphery of
the duct and not immediately adjacent to the necrotic area (asterisk) (E).
Strong nuclear and weak cytoplasmic DEC1 expression in an invasive ductal
carcinoma; the inset demonstrates strong nuclear and cytoplasmic staining
in a different invasive ductal carcinoma (F). Fibroblast (thin arrows) and
macrophage (thick arrows) DEC1 staining adjacent to an island of invasive
ductal carcinoma (G). Strong DEC1 endothelial cell positivity in tumour-
associated vessels in an invasive ductal carcinoma showing weak DEC
immunopositivity (H).
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ypatchy expression of DEC1, suggesting that it is unlikely to
play a role in normal cyclical physiological changes. However,
there was increased expression of DEC1 in metaplastic changes, in
keeping with its role in cellular differentiation (Shapland et al,
1988; Fisher et al, 1996).
The incremental increase in DEC1 expression in both the
nuclear and cytoplasmic neoplastic cell compartments during
progression of normal to in situ and invasive carcinoma suggests
that DEC1 plays a role in breast cancer progression. It may
additionally have a role in stroma since expression was frequently
observed particularly in fibroblasts and endothelium. However, the
mechanism of DEC1 regulation in tumour cells must be VHL
independent since, unlike conventional clear-cell renal cell
carcinomas, breast cancers have an intact VHL gene. This is
emphasised by the strong DEC1 staining of other tumour elements,
including endothelial cells that are genotypically normal. Although
little is known about the regulation of DEC1, prostaglandin E2 and
transforming growth factor (TGF)-b have been reported to induce
DEC1, TGF-b being frequently expressed in breast carcinomas
(Zawel et al, 2002; Bek et al, 2003).
Since Stra13 is associated with growth arrest, the increase in
DEC1 expression in tumours may seem paradoxical (Boudjelal
et al, 1997; Sun and Taneja, 2000). However, the level of expression
alters the effect, with medium levels resulting in an increased
proliferation rate of approximately two- to three-fold, with the
higher-expressing clones not being viable (Boudjelal et al, 1997;
Sun and Taneja, 2000).
DEC1 is induced by hypoxia through a HRE (Miyazaki et al,
2002), and in our study we have demonstrated a significant
association with HIF-1a and the hypoxia-induced gene angiogenin
(Hartmann et al, 1999), supporting its induction by this
microenvironmental stress in breast cancer. Nevertheless, unlike
CAIX (Wykoff et al, 2000a), we did not observe upregulation of
DEC1 immediately adjacent to areas of necrosis in either in situ or
invasive carcinomas, similar to findings obtained by mRNA in situ
hybridisation studies (Peter Watson, personal communication).
Indeed, DEC1 was increasingly expressed in cell layers distant
from the edge of the necrotic zone. This pattern of expression
overlaps with that of CAIX and HIF-1a, with HIF-1a located
throughout tumours, showing that there is a differential pattern of
localisation of hypoxia-associated molecules. The reasons for this
are not clear, but may reflect the different half-lives of the proteins
and/or regulation by other factors such as TGF-b, the latter of
which is associated with breast cancer progression (Gorsch et al,
1992; Zawel et al, 2002).
Nevertheless, the marked induction of this differentiation
factor by hypoxia within tumours suggests that it may be
predominantly regulated by hypoxia and that hypoxia may have
a role in differentiation. Indeed, a positive association between
tumour grade and HIF-1a has been reported. Thus, the significant
positive correlation between high DEC1 expression and high
tumour grade that we describe, an association that has been
reported in lung cancers (Giatromanolaki et al, 2003) is in
accordance with its induction by HIF (Bos et al, 2001) and
Stra13’s ability to repress differentiation in embryogenesis and
adipocytes (Boudjelal et al, 1997; Yun et al, 2002). The mechanism
of this repression may be through interaction with other
transcription factors such as TFB, TFIIB and USF, since DEC1,
unlike other family members, does not bind to E box, N box or C
box sequences (Yun et al, 2002). DEC1 is also reported to
antagonise serum deprivation-induced apoptosis through selective
repression of pro-caspases 3, 7 and 9, but not 8, suggesting the
blockage of mitochondrial apoptotic pathways (Li et al, 2002).
Thus, DEC1 may play a further role in rescuing high-grade
tumours from widespread programmed cell death (Gandhi et al,
1998).
Although our findings suggest that DEC1 may contribute to
mediating the aggressive phenotype of hypoxic tumours, we did
not demonstrate a significant association between DEC1-positive
tumours and relapse-free or overall survival that has been reported
for hypoxic node-negative and node-positive breast tumours
(Schindl et al, 2002; Bos et al, 2003). This is likely to be due to
the accumulated effects of the many classes of genes that the HIF
response activates. Nevertheless, data derived from mouse
podocytes suggest that DEC1 may play an important cytoprotec-
tive role against reactive oxygen species through upregulating
haeme oxygenase-1 and decreasing NADPH oxidase (Bek et al,
2003). Thus, the level of DEC1 in tumours should be assessed for a
relation in response to radiotherapy.
Recently, DEC2, a human DEC1 homologue, has been
cloned and has also been shown to be hypoxically induced
(Fujimoto et al, 2001; Miyazaki et al, 2002). Data to date suggest
that, whereas DEC1 is mostly expressed in cancer, DEC2
expression is higher in the adjacent normal tissues. Indeed,
forced expression of DEC1 resulted in repression in the activity of
a DEC2 promoter reporter (Azmi et al, 2003). It will thus be
of interest to establish the role of this protein in the hypoxic
pathway.
In summary, we have shown that DEC1 expression increases on
progression from normal to in situ and invasive carcinoma,
supporting a significant role for this transcription factor in breast
neoplasia. We have further shown that DEC1 expression is strongly
associated with HIF-1a, the hypoxically induced protein angio-
genin and tumour grade, suggesting a role for DEC1 in blocking
tumour differentiation and potentially apoptosis. These findings
provide mechanisms by which breast tumours in a hypoxic
environment acquire a more aggressive phenotype (Schindl et al,
2002).
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Figure 2 Kaplan and Meier relapse-free survival (upper graph) and
overall survival curves (lower graph) stratified by DEC1 expression.
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